Peel Hunt Reaffirms Buy Rating for Silence Therapeutics (LON:SLN)

Peel Hunt reaffirmed their buy rating on shares of Silence Therapeutics (LON:SLN) in a report issued on Wednesday, October 3rd.

LON:SLN opened at GBX 117.50 ($1.54) on Wednesday. Silence Therapeutics has a one year low of GBX 71.88 ($0.94) and a one year high of GBX 254.75 ($3.33).

Silence Therapeutics (LON:SLN) last issued its earnings results on Tuesday, September 11th. The company reported GBX (12.40) (($0.16)) earnings per share (EPS) for the quarter. Silence Therapeutics had a negative return on equity of 21.42% and a negative net margin of 34,475.00%.

Silence Therapeutics Company Profile

Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various candidates for the treatment of cancer, iron overload disorders, cardiovascular disease, alcohol use disorder, and other metabolic diseases.

Featured Story: New Google Finance Tool and Screening Stocks

Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply